Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03349060) enrolled 387 adults with atopic dermatitis (eczema). Participants were randomly assigned to one of three groups: a daily 100 mg dose of the study drug PF-04965842 (156 people), a daily 200 mg dose (154 people), or a placebo — a dummy pill with no active ingredient (77 people). The trial ran for 12 weeks and was measuring changes in skin appearance and itch severity using several standardised rating scales. The reported data shows the following for the two main outcomes measured at week 12. On a skin clearance scale called the IGA — where doctors rated overall skin condition from 0 (clear) to 4 (severe) — 23.7% of participants in the 100 mg group and 43.8% in the 200 mg group were rated as "clear" or "almost clear," compared with 7.9% in the placebo group. On a separate body-wide skin severity score called the EASI, 39.7% of the 100 mg group and 62.7% of the 200 mg group showed at least a 75% improvement in their score from the start of the trial, compared with 11.8% in the placebo group. For itching, the reported data shows that by week 12, 37.7% of the 100 mg group and 57.2% of the 200 mg group reported at least a 4-point improvement on a 0–10 itch scale, compared with 15.3% in the placebo group. A broader symptom diary covering 11 skin complaints (scored 0–10) showed average score reductions of 2.2 points (100 mg group), 3.2 points (200 mg group), and 1.1 points (placebo group) from the start to week 12. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 42162528) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 12 years of age or older and weigh at least 40 kg (about 88 pounds)
- You have been diagnosed with atopic dermatitis (eczema) for at least 1 year, and your symptoms are currently moderate to severe (based on specific scoring measurements the trial team will assess)
- You have recently tried topical (applied to skin) treatments for your eczema that did not work well enough, you could not tolerate them, or your condition requires oral/injected medications to keep it under control
Who may not be able to join:
- You are unwilling to stop your current eczema medications before the study starts, or you need to take medications that are not allowed during the study
- You have previously been treated with a type of medication called a JAK inhibitor
- You have another active skin disease or condition affecting your skin that is not eczema
- You have a history of certain medical conditions, including blood clotting problems, low platelet counts, heart rhythm abnormalities, certain infections, cancer, or other serious medical conditions (confirm with trial site)
- You are currently pregnant, breastfeeding, or are able to become pregnant but are unwilling to use contraception during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12; Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response of >=75 Percent (%) Improvement From Baseline at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.